London
· Delayed Price · Currency is GBP · Price in GBX Faron Pharmaceuticals Oy Statistics
Total Valuation
Faron Pharmaceuticals Oy has a market cap or net worth of GBP 201.40 million. The enterprise value is 186.77 million.
| Market Cap | 201.40M |
| Enterprise Value | 186.77M |
Important Dates
The next estimated earnings date is Thursday, February 27, 2025.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Faron Pharmaceuticals Oy has 104.62 million shares outstanding. The number of shares has increased by 14.45% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 104.62M |
| Shares Change (YoY) | +14.45% |
| Shares Change (QoQ) | +4.96% |
| Owned by Insiders (%) | 24.28% |
| Owned by Institutions (%) | 9.50% |
| Float | 73.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 172.27 |
| P/TBV Ratio | 810.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.97 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 9.23.
| Current Ratio | 1.45 |
| Quick Ratio | 1.28 |
| Debt / Equity | 9.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -70.00% |
| Return on Capital (ROIC) | -186.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -788,198 |
| Employee Count | 34 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.10% in the last 52 weeks. The beta is 0.28, so Faron Pharmaceuticals Oy's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -20.10% |
| 50-Day Moving Average | 178.90 |
| 200-Day Moving Average | 164.34 |
| Relative Strength Index (RSI) | 47.27 |
| Average Volume (20 Days) | 11,785 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.93M |
| Pretax Income | -26.76M |
| Net Income | -26.80M |
| EBITDA | -22.78M |
| EBIT | -22.93M |
| Earnings Per Share (EPS) | -0.39 |
Balance Sheet
The company has 25.42 million in cash and 10.79 million in debt, giving a net cash position of 14.63 million or 0.14 per share.
| Cash & Cash Equivalents | 25.42M |
| Total Debt | 10.79M |
| Net Cash | 14.63M |
| Net Cash Per Share | 0.14 |
| Equity (Book Value) | 1.17M |
| Book Value Per Share | 0.01 |
| Working Capital | 8.88M |
Cash Flow
| Operating Cash Flow | -17.09M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Faron Pharmaceuticals Oy does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.45% |
| Shareholder Yield | -14.45% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |